[1] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359–E386. doi:  10.1002/ijc.29210
[2] Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med, 2006, 355(1): 11–20. doi:  10.1056/NEJMoa055531
[3] Hwang JH. Understanding gastric cancer risk factors: we need to close the gap[J]. Gut Liver, 2018, 12(1): 1–2. doi:  10.5009/gnl17503
[4] Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J]. Cell, 1993, 75(5): 843–854. doi:  10.1016/0092-8674(93)90529-Y
[5] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2): 281–297. doi:  10.1016/S0092-8674(04)00045-5
[6] Zhao HN, Yu XT, Ding YF, et al. MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2[J]. Oncotarget, 2016, 7(33): 53254–53268.
[7] Wang L, Chen Y, Jiang Y, et al. MiR-199a-3p affects the multi-chemoresistance of osteosarcoma through targeting AK4[J]. BMC Cancer, 2018, 18(1): 631. doi:  10.1186/s12885-018-4460-0
[8] Huang LM, Hu CQ, Cao H, et al. MicroRNA-29c increases the chemosensitivity of pancreatic cancer cells by inhibiting USP22 mediated autophagy[J]. Cell Physiol Biochem, 2018, 47(2): 747–758. doi:  10.1159/000490027
[9] Wang M, Cai WR, Meng R, et al. miR-485-5p suppresses breast cancer progression and chemosensitivity by targeting survivin[J]. Biochem Biophys Res Commun, 2018, 501(1): 48–54. doi:  10.1016/j.bbrc.2018.04.129
[10] Lu MJ, Wang TS, He MF, et al. Tumor suppressor role of miR-3622b-5p in ERBB2-positive cancer[J]. Oncotarget, 2017, 8(14): 23008–23019.
[11] Qiu TZ, Zhou X, Wang J, et al. MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer[J]. FEBS Lett, 2014, 588(7): 1168–1177. doi:  10.1016/j.febslet.2014.02.054
[12] Zhao DS, Chen Y, Jiang H, et al. Serum miR-210 and miR-30a expressions tend to revert to fetal levels in Chinese adult patients with chronic heart failure[J]. Cardiovasc Pathol, 2013, 22(6): 444–450. doi:  10.1016/j.carpath.2013.04.001
[13] Zhou X, Zhu W, Li H, et al. Diagnostic value of a plasma microRNA signature in gastric cancer: a microRNA expression analysis[J]. Sci Rep, 2015, 5: 11251. doi:  10.1038/srep11251
[14] Zhu W, Shan X, Wang TS, et al. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines[J]. Int J Cancer, 2010, 127(11): 2520–2529. doi:  10.1002/ijc.25260
[15] Zhu W, Xu HG, Zhu DX, et al. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP[J]. Cancer Chemother Pharmacol, 2012, 69(3): 723–731. doi:  10.1007/s00280-011-1752-3
[16] Xia L, Zhang DX, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells[J]. Int J Cancer, 2008, 123(2): 372–379. doi:  10.1002/ijc.23501
[17] Zhu DX, Zhu W, Fang C, et al. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes[J]. Carcinogenesis, 2012, 33(7): 1294–1301. doi:  10.1093/carcin/bgs179
[18] Holohan C, van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm[J]. Nat Rev Cancer, 2013, 13(10): 714–726. doi:  10.1038/nrc3599
[19] Hayes JD, Wolf CR. Molecular mechanisms of drug resistance[J]. Biochem J, 1990, 272(2): 281–295. doi:  10.1042/bj2720281
[20] Sharma SV, Lee DY, Li BH, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations[J]. Cell, 2010, 141(1): 69–80. doi:  10.1016/j.cell.2010.02.027
[21] Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs[J]. Drug Resist Updat, 2007, 10(1–2): 59–67.
[22] Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy[J]. Nat Rev Cancer, 2008, 8(3): 193–204. doi:  10.1038/nrc2342
[23] Selvakumaran M, Pisarcik DA, Bao RD, et al. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines[J]. Cancer Res, 2003, 63(6): 1311–1316.
[24] Liu HN, Peng Q, Yang G, et al. miR-181b inhibits chemoresistance in cisplatin-resistant H446 small cell lung cancer cells by targeting Bcl-2[J]. Arch Med Sci, 2018, 14(4): 745–751.
[25] Gao JL, Wu N, Liu XH, et al. MicroRNA-142-3p inhibits cell proliferation and chemoresistance in ovarian cancer via targeting sirtuin 1[J]. Exp Ther Med, 2018, 15(6): 5205–5214.
[26] Feng Q, He P, Wang Y. MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer[J]. Gene, 2018, 658: 152–158. doi:  10.1016/j.gene.2018.03.013
[27] Chen X, Duan N, Zhang CG, et al. Survivin and tumorigenesis: molecular mechanisms and therapeutic strategies[J]. J Cancer, 2016, 7(3): 314–323. doi:  10.7150/jca.13332
[28] Xiong CH, Liu HP, Chen ZX, et al. Prognostic role of survivin in renal cell carcinoma: a system review and meta-analysis[J]. Eur J Intern Med, 2016, 33: 102–107. doi:  10.1016/j.ejim.2016.06.009
[29] Peery RC, Liu JY, Zhang JT. Targeting survivin for therapeutic discovery: past, present, and future promises[J]. Drug Discov Today, 2017, 22(10): 1466–1477. doi:  10.1016/j.drudis.2017.05.009
[30] Nabilsi NH, Broaddus RR, Loose DS. DNA methylation inhibits p53-mediated survivin repression[J]. Oncogene, 2009, 28(19): 2046–2050. doi:  10.1038/onc.2009.62
[31] Huang JC, Lyu H, Wang JX, et al. MicroRNA regulation and therapeutic targeting of survivin in cancer[J]. Am J Cancer Res, 2015, 5(1): 20–31.